Research programme: bifunctional short hairpin cancer therapeutics - Gradalis/Mary Crowley Research Center

Drug Profile

Research programme: bifunctional short hairpin cancer therapeutics - Gradalis/Mary Crowley Research Center

Alternative Names: pbi-shPDX-1 LP; pbi-shRNA K-ras LP

Latest Information Update: 06 Mar 2012

Price : $50

At a glance

  • Originator Gradalis; Mary Crowley Cancer Research Center
  • Class Lipids; Small interfering RNA
  • Mechanism of Action Pancreatic and duodenal homeobox 1 protein inhibitors; RNA interference; Stathmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Mar 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top